A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test

As of October 2020, there is still no specific drug to treat COVID-19 as it rages worldwide. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet fully validated. We administered favipira...

Descripción completa

Detalles Bibliográficos
Autores principales: Murai, Yushi, Kawasuji, Hitoshi, Takegoshi, Yusuke, Kaneda, Makito, Kimoto, Kou, Ueno, Akitoshi, Miyajima, Yuki, Kawago, Koyomi, Fukui, Yasutaka, Ogami, Chika, Sakamaki, Ippei, Tsuji, Yasuhiro, Morinaga, Yoshitomo, Yamamoto, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970795/
https://www.ncbi.nlm.nih.gov/pubmed/33746092
http://dx.doi.org/10.1016/j.ijid.2021.03.048
_version_ 1783666482650021888
author Murai, Yushi
Kawasuji, Hitoshi
Takegoshi, Yusuke
Kaneda, Makito
Kimoto, Kou
Ueno, Akitoshi
Miyajima, Yuki
Kawago, Koyomi
Fukui, Yasutaka
Ogami, Chika
Sakamaki, Ippei
Tsuji, Yasuhiro
Morinaga, Yoshitomo
Yamamoto, Yoshihiro
author_facet Murai, Yushi
Kawasuji, Hitoshi
Takegoshi, Yusuke
Kaneda, Makito
Kimoto, Kou
Ueno, Akitoshi
Miyajima, Yuki
Kawago, Koyomi
Fukui, Yasutaka
Ogami, Chika
Sakamaki, Ippei
Tsuji, Yasuhiro
Morinaga, Yoshitomo
Yamamoto, Yoshihiro
author_sort Murai, Yushi
collection PubMed
description As of October 2020, there is still no specific drug to treat COVID-19 as it rages worldwide. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet fully validated. We administered favipiravir to a 64-year-old female patient with COVID-19. Her symptoms resolved quickly after the start of treatment, with reduction of SARS-CoV-2 viral load, but she developed a fever again on day 12. Since the fever was relieved by discontinuation of favipiravir, and based on positive results with a drug-induced lymphocyte stimulation test, we diagnosed her with favipiravir-induced drug fever. A decrease in the serum concentration of favipiravir was observed along with resolution of the fever. The present case suggests that drug fever should be considered in the differential diagnosis of relapsing fever episodes in COVID-19 patients receiving favipiravir.
format Online
Article
Text
id pubmed-7970795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-79707952021-03-19 A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test Murai, Yushi Kawasuji, Hitoshi Takegoshi, Yusuke Kaneda, Makito Kimoto, Kou Ueno, Akitoshi Miyajima, Yuki Kawago, Koyomi Fukui, Yasutaka Ogami, Chika Sakamaki, Ippei Tsuji, Yasuhiro Morinaga, Yoshitomo Yamamoto, Yoshihiro Int J Infect Dis Case Report As of October 2020, there is still no specific drug to treat COVID-19 as it rages worldwide. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet fully validated. We administered favipiravir to a 64-year-old female patient with COVID-19. Her symptoms resolved quickly after the start of treatment, with reduction of SARS-CoV-2 viral load, but she developed a fever again on day 12. Since the fever was relieved by discontinuation of favipiravir, and based on positive results with a drug-induced lymphocyte stimulation test, we diagnosed her with favipiravir-induced drug fever. A decrease in the serum concentration of favipiravir was observed along with resolution of the fever. The present case suggests that drug fever should be considered in the differential diagnosis of relapsing fever episodes in COVID-19 patients receiving favipiravir. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-05 2021-03-18 /pmc/articles/PMC7970795/ /pubmed/33746092 http://dx.doi.org/10.1016/j.ijid.2021.03.048 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Murai, Yushi
Kawasuji, Hitoshi
Takegoshi, Yusuke
Kaneda, Makito
Kimoto, Kou
Ueno, Akitoshi
Miyajima, Yuki
Kawago, Koyomi
Fukui, Yasutaka
Ogami, Chika
Sakamaki, Ippei
Tsuji, Yasuhiro
Morinaga, Yoshitomo
Yamamoto, Yoshihiro
A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test
title A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test
title_full A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test
title_fullStr A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test
title_full_unstemmed A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test
title_short A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test
title_sort case of covid-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970795/
https://www.ncbi.nlm.nih.gov/pubmed/33746092
http://dx.doi.org/10.1016/j.ijid.2021.03.048
work_keys_str_mv AT muraiyushi acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT kawasujihitoshi acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT takegoshiyusuke acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT kanedamakito acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT kimotokou acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT uenoakitoshi acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT miyajimayuki acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT kawagokoyomi acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT fukuiyasutaka acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT ogamichika acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT sakamakiippei acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT tsujiyasuhiro acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT morinagayoshitomo acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT yamamotoyoshihiro acaseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT muraiyushi caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT kawasujihitoshi caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT takegoshiyusuke caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT kanedamakito caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT kimotokou caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT uenoakitoshi caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT miyajimayuki caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT kawagokoyomi caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT fukuiyasutaka caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT ogamichika caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT sakamakiippei caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT tsujiyasuhiro caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT morinagayoshitomo caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest
AT yamamotoyoshihiro caseofcovid19diagnosedwithfavipiravirinduceddrugfeverbasedonapositivedruginducedlymphocytestimulationtest

Ejemplares similares